Skip to main content
. 2021 Apr 6;10(7):1527. doi: 10.3390/jcm10071527

Figure 2.

Figure 2

Real-world studies by ivacaftor-treated cohort size. Note: Studies do not sum to 57 because the Long-Term Safety Study reported results separately for US and UK cohorts treated with ivacaftor in cross-sectional [29] and disease progression analyses [30]. pwCF: people with cystic fibrosis.